Stéphane Beaudet, president of Genopole
- Stéphane Beaudet
Stéphane Beaudet mayor of Évry-Courcouronnes, vice-president of the Île-de-France Administrative Region, and first vice-president of the Grand Paris Sud Urban Area responsible for territorial attractiveness, has been elected as president of Genopole. He succeeds Marianne Duranton, president of Genopole since 1 April 2016.
"Genopole is in the DNA of Évry-Courcouronnes. The biocluster was brought to be by a handful of visionary pioneers who, in twenty years, have anchored in the Île-de-France Region and more precisely in the Grand Paris Sud community of Essonne a major edifice for not only tomorrow’s health but also today’s economic development. Presiding over the destiny of GIP Genopole, herein lies the challenge for me : enabling the continuity of research, testing and experimentation to discover new molecules and conceive new treatments while offering perspectives for development to biotech investors and entrepreneurs so that the employment and wealth thus created serve our territory and our economic fabric."
Marianne Duranton, Vice-President of Genopole
Marianne Duranton has been a representative for the Essonne administrative department, a councillor for the Morsang-sur-Orge municipality and a councillor for the Ile-de-France administrative region.
She holds a master’s degree in political sciences from Panthéon-Assas (Paris 2) University. Particularly, from 2007 to 2010 she worked with Martin Hirsch while at his post of high commissioner for active solidarity against poverty. Marianne Duranton is also currently the administrative director of the Union of Democrats and Independents (UDI) political party.
"Genopole is a flagship for the Essonne department and the Ile-de-France region. It was a precursor to what the Grand Paris Project is hoping to develop now, in particular with the Paris-Saclay cluster. For our territory, the Genopole model is a major asset that must be supported and developed in coherency with our other projects. I hope to add my energy to the momentum created by Genopole for research in genomics, which, in particular, will contribute to the emergence of tomorrow’s personalized medicine and bring hope to patients who had none."